Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
ELOS's Cash to Debt is ranked higher than
96% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ELOS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ELOS' s Cash to Debt Range Over the Past 10 Years
Min: 65.7  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.74
ELOS's Equity to Asset is ranked higher than
68% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ELOS: 0.74 )
Ranked among companies with meaningful Equity to Asset only.
ELOS' s Equity to Asset Range Over the Past 10 Years
Min: 0.61  Med: 0.76 Max: 0.89
Current: 0.74
0.61
0.89
F-Score: 6
Z-Score: 3.64
M-Score: -2.50
WACC vs ROIC
11.90%
-3.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -1.95
ELOS's Operating margin (%) is ranked lower than
56% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. ELOS: -1.95 )
Ranked among companies with meaningful Operating margin (%) only.
ELOS' s Operating margin (%) Range Over the Past 10 Years
Min: -43.96  Med: -2.35 Max: 29.62
Current: -1.95
-43.96
29.62
Net-margin (%) -1.88
ELOS's Net-margin (%) is ranked lower than
55% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. ELOS: -1.88 )
Ranked among companies with meaningful Net-margin (%) only.
ELOS' s Net-margin (%) Range Over the Past 10 Years
Min: -43.1  Med: -1.27 Max: 33.9
Current: -1.88
-43.1
33.9
ROE (%) -2.47
ELOS's ROE (%) is ranked lower than
57% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 0.98 vs. ELOS: -2.47 )
Ranked among companies with meaningful ROE (%) only.
ELOS' s ROE (%) Range Over the Past 10 Years
Min: -19.9  Med: -1.43 Max: 23.36
Current: -2.47
-19.9
23.36
ROA (%) -1.84
ELOS's ROA (%) is ranked lower than
54% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: -0.34 vs. ELOS: -1.84 )
Ranked among companies with meaningful ROA (%) only.
ELOS' s ROA (%) Range Over the Past 10 Years
Min: -14.56  Med: -1.06 Max: 20.05
Current: -1.84
-14.56
20.05
ROC (Joel Greenblatt) (%) -8.93
ELOS's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 4.07 vs. ELOS: -8.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ELOS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -397.3  Med: -15.02 Max: 212.39
Current: -8.93
-397.3
212.39
Revenue Growth (3Y)(%) 0.90
ELOS's Revenue Growth (3Y)(%) is ranked lower than
62% of the 234 Companies
in the Global Medical Devices industry.

( Industry Median: 3.70 vs. ELOS: 0.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ELOS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 9.80 Max: 190.6
Current: 0.9
0
190.6
EBITDA Growth (3Y)(%) -17.70
ELOS's EBITDA Growth (3Y)(%) is ranked lower than
81% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. ELOS: -17.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ELOS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -47.6  Med: 3.20 Max: 99.5
Current: -17.7
-47.6
99.5
EPS Growth (3Y)(%) 66.10
ELOS's EPS Growth (3Y)(%) is ranked higher than
91% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. ELOS: 66.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ELOS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.6  Med: -0.40 Max: 98.4
Current: 66.1
-64.6
98.4
» ELOS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ELOS Guru Trades in Q2 2015

Jim Simons 931,703 sh (+11.08%)
Mario Gabelli 24,000 sh (unchged)
Chuck Royce 437,559 sh (-22.19%)
Charles Brandes 570,430 sh (-34.15%)
» More
Q3 2015

ELOS Guru Trades in Q3 2015

Chuck Royce 618,459 sh (+41.34%)
Mario Gabelli 24,000 sh (unchged)
Charles Brandes 570,370 sh (-0.01%)
Jim Simons 912,780 sh (-2.03%)
» More
Q4 2015

ELOS Guru Trades in Q4 2015

Ronald Muhlenkamp 10,255 sh (New)
Charles Brandes 1,745,669 sh (+206.06%)
Chuck Royce 663,159 sh (+7.23%)
Mario Gabelli 24,000 sh (unchged)
Jim Simons 900,606 sh (-1.33%)
» More
Q1 2016

ELOS Guru Trades in Q1 2016

Charles Brandes 2,509,446 sh (+43.75%)
Chuck Royce 713,159 sh (+7.54%)
Jim Simons 928,806 sh (+3.13%)
Mario Gabelli 24,000 sh (unchged)
Ronald Muhlenkamp Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ELOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:OTCPK:IPDQF, NAS:IRMD, NAS:TNDM, NAS:RTIX, OTCPK:VICA, NAS:AXGN, OTCPK:DMTRF, AMEX:CVRS, NAS:SURG, NAS:GNMK, OTCPK:NMRD, NAS:EXAC, NAS:XENT, NAS:VRAY, NAS:AVGR, OTCPK:MZRTF, OTCPK:LFWWF, NYSE:IVC, NAS:IRIX, NAS:CUTR » details
Traded in other countries:FGD.Germany,
Syneron Medical Ltd designs, develops & markets aesthetic medical products based on its proprietary technologies. Its offers Skin Rejuvenation, Age Spots, Cellulite Reduction, Acne, & Hair Removal among others.

Syneron Medical Ltd., was incorporated in the State of Israel in July 2000. The Company completed its initial public offering of ordinary shares in August 2004. It designs, develops and markets aesthetic medical products based on its various technologies including its proprietary Electro-Optical Synergy, or ELOS, technology, which uses the synergy between electrical energy, including radiofrequency or RF energy, and optical energy to provide effective, safe and affordable aesthetic medical treatments. The Company's products, which it sells mainly to physicians and other practitioners, target non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin and laser-assisted lipolysis and topical skin brightening products. ELOS provides performance advantages over existing technologies that rely solely on optical energy. The Company's proprietary ELOS technology, which combines optical and electrical energy, enhances the user's ability to accurately target the tissue to be treated and enables real-time measurement of skin temperature, resulting in increased patient safety and comfort and improved treatment results. Its patent portfolio (including patents held by subsidiaries) consisted of 140 issued U.S. patents.The Company's trademarks include Syneron, Elos, Candela, Ultrashape, Litetouch, VelaShape, VelaSmooth, Sublative, eTwo, eMax, ePRIME, eLase, elosPlus, Elure, Motif, Co2re, eMatrix, Matrix IR, Matrix RF, Refirme. It competes with large pharmaceutical companies that have entered the aesthetic device market, such as Valeant Pharmaceuticals International Inc. (which acquired Solta Medical Inc. in 2014), Merz Pharma Group (which acquired Ulthera, Inc. in 2014) and Actevis PLC (which acquired Allergan, Inc. in 2014). Its products compete against conventional non-light-based treatments, including Botox (neurotoxins) and hyaluronic acid injections, face lifts, sclerotherapy, electrolysis, liposuction, chemical peels and microdermabrasion. The Company's products are medical devices and cosmetics subject to extensive and rigorous regulation by the FDA, as well as other U.S. and foreign regulatory bodies.

Ratios

vs
industry
vs
history
Forward P/E 36.90
ELOS's Forward P/E is ranked lower than
83% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 24.15 vs. ELOS: 36.90 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.26
ELOS's P/B is ranked higher than
79% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. ELOS: 1.26 )
Ranked among companies with meaningful P/B only.
ELOS' s P/B Range Over the Past 10 Years
Min: 0.58  Med: 1.61 Max: 8.18
Current: 1.26
0.58
8.18
P/S 0.94
ELOS's P/S is ranked higher than
79% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.99 vs. ELOS: 0.94 )
Ranked among companies with meaningful P/S only.
ELOS' s P/S Range Over the Past 10 Years
Min: 0.84  Med: 1.87 Max: 14.12
Current: 0.94
0.84
14.12
EV-to-EBITDA 60.14
ELOS's EV-to-EBITDA is ranked lower than
90% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 17.82 vs. ELOS: 60.14 )
Ranked among companies with meaningful EV-to-EBITDA only.
ELOS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -294.8  Med: 13.00 Max: 172.2
Current: 60.14
-294.8
172.2
Current Ratio 2.82
ELOS's Current Ratio is ranked lower than
52% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.88 vs. ELOS: 2.82 )
Ranked among companies with meaningful Current Ratio only.
ELOS' s Current Ratio Range Over the Past 10 Years
Min: 2.59  Med: 3.91 Max: 10.72
Current: 2.82
2.59
10.72
Quick Ratio 2.06
ELOS's Quick Ratio is ranked lower than
51% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. ELOS: 2.06 )
Ranked among companies with meaningful Quick Ratio only.
ELOS' s Quick Ratio Range Over the Past 10 Years
Min: 1.9  Med: 3.63 Max: 10.39
Current: 2.06
1.9
10.39
Days Inventory 131.87
ELOS's Days Inventory is ranked higher than
52% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 136.99 vs. ELOS: 131.87 )
Ranked among companies with meaningful Days Inventory only.
ELOS' s Days Inventory Range Over the Past 10 Years
Min: 56.52  Med: 108.11 Max: 205.18
Current: 131.87
56.52
205.18
Days Sales Outstanding 75.72
ELOS's Days Sales Outstanding is ranked lower than
57% of the 271 Companies
in the Global Medical Devices industry.

( Industry Median: 68.67 vs. ELOS: 75.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
ELOS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 69.22  Med: 80.76 Max: 120.06
Current: 75.72
69.22
120.06
Days Payable 64.40
ELOS's Days Payable is ranked higher than
53% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 61.70 vs. ELOS: 64.40 )
Ranked among companies with meaningful Days Payable only.
ELOS' s Days Payable Range Over the Past 10 Years
Min: 50.87  Med: 67.37 Max: 131.41
Current: 64.4
50.87
131.41

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 2.21
ELOS's Price/Net Current Asset Value is ranked higher than
88% of the 205 Companies
in the Global Medical Devices industry.

( Industry Median: 6.53 vs. ELOS: 2.21 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ELOS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.86  Med: 2.81 Max: 8.12
Current: 2.21
0.86
8.12
Price/Tangible Book 1.50
ELOS's Price/Tangible Book is ranked higher than
83% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 3.76 vs. ELOS: 1.50 )
Ranked among companies with meaningful Price/Tangible Book only.
ELOS' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.71  Med: 2.06 Max: 7.89
Current: 1.5
0.71
7.89
Price/Projected FCF 13.44
ELOS's Price/Projected FCF is ranked lower than
96% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. ELOS: 13.44 )
Ranked among companies with meaningful Price/Projected FCF only.
ELOS' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.32 Max: 43.93
Current: 13.44
0.52
43.93
Price/Median PS Value 0.50
ELOS's Price/Median PS Value is ranked higher than
86% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. ELOS: 0.50 )
Ranked among companies with meaningful Price/Median PS Value only.
ELOS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.49  Med: 1.15 Max: 7.16
Current: 0.5
0.49
7.16
Earnings Yield (Greenblatt) (%) -2.90
ELOS's Earnings Yield (Greenblatt) (%) is ranked lower than
60% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. ELOS: -2.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ELOS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 7.40 Max: 6887.2
Current: -2.9
0.1
6887.2

More Statistics

Revenue (TTM) (Mil) $283.2
EPS (TTM) $ -0.15
Beta1.35
Short Percentage of Float2.00%
52-Week Range $6.10 - 11.41
Shares Outstanding (Mil)35.27

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 297 320
EPS ($) 0.20 0.50
EPS w/o NRI ($) 0.20 0.50
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for ELOS

Headlines

Articles On GuruFocus.com
Retrophin At All-Time High Levels on RE-024 FDA-Status; Syneron Settles Legal Battle Jun 05 2015 
Why Is Seth Klarman Loading Up on Syneron Medical? Aug 29 2011 
Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
Seth Klarman More Than Doubles Holdings in Syneron Medical Jul 12 2011 
Top Seth Klarman Holding, ELOS Rockets Up 20% Feb 16 2011 
Baupost’s Seth Klarman Buys Enzon Inc., Viasat Inc., Sells Horizon Lines Inc., News Corp., PDL Bio Nov 12 2009 
Seth Klarman Buys First American Corp., Universal Compression Holdings, School Specialty Inc., Sells Aug 13 2007 
Seth Klarman Buys Home Depot Inc., InfoSpace Inc., Multimedia Games Inc., Sells Laidlaw Internationa Nov 13 2006 

More From Other Websites
ETF’s with exposure to Syneron Medical Ltd. : May 23, 2016 May 23 2016
Syneron Medical Ltd. :ELOS-US: Earnings Analysis: Q1, 2016 By the Numbers May 20 2016
Edited Transcript of ELOS earnings conference call or presentation 19-May-16 12:30pm GMT May 19 2016
Syneron Medical Reports First Quarter 2016 Revenue of $68.7 Million May 19 2016
Syneron Medical reports 1Q loss May 19 2016
Syneron Medical reports 1Q loss May 19 2016
Q1 2016 Syneron Medical Ltd Earnings Release - Before Market Open May 19 2016
Syneron Medical Reports First Quarter 2016 Revenue of $68.7 Million May 19 2016
Syneron Medical to Report First Quarter 2016 Financial Results on May 19, 2016 Apr 27 2016
Syneron Medical to Report First Quarter 2016 Financial Results on May 19, 2016 Apr 27 2016
Syneron Candela Leads Energy Innovation Discussions at 36th Annual ASLMS Conference Mar 31 2016
Syneron Candela Leads Energy Innovation Discussions at 36th Annual ASLMS Conference Mar 31 2016
SYNERON MEDICAL LTD. Financials Mar 24 2016
Syneron Medical Ltd. Announces Availability of its Annual Report on Form 20-F through its Website Mar 21 2016
Syneron Medical Ltd. Announces Availability of its Annual Report on Form 20-F through its Website Mar 21 2016
Syneron Medical and Allergan Announce U.S. Aesthetics Collaboration Mar 05 2016
Syneron Candela to Introduce New Technologies at the 2016 American Academy of Dermatology (AAD)... Mar 03 2016
Syneron Medical Ltd. Earnings Analysis: 2015 By the Numbers Feb 24 2016
Edited Transcript of ELOS earnings conference call or presentation 22-Feb-16 1:30pm GMT Feb 22 2016
Syneron Medical posts 4Q profit Feb 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)